Ali A. Habib

•Clinical Professor, Department of Neurology, University of California, Irvine

•Director, EMG laboratory, University of California, Irvine

Biography

Ali A. Habib, M.B., B.S., is Clinical Professor in the Department of Neurology at the University of California, Irvine, where he also serves as Director of the EMG Laboratory and Director of the Neuromuscular Disorders Fellowship. He received his medical degree from The Aga Khan University Medical College in Karachi, Pakistan, and completed fellowships in Amyotrophic Lateral Sclerosis at Columbia University and Clinical Neurophysiology at New York Presbyterian Hospital, Columbia University. Habib is board certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.

Habib's clinical and research focus centers on neuromuscular disorders, particularly myasthenia gravis. He has served as principal investigator or lead investigator on over 35 clinical trials evaluating novel therapeutics for myasthenia gravis, amyotrophic lateral sclerosis, and other neuromuscular conditions. His research contributions include more than 50 peer-reviewed publications and numerous presentations at national and international conferences. He co-directs the Annual UC Irvine Neuromuscular Colloquium and the Annual UC Irvine Neuromuscular Pathology Colloquium, and serves as Course Director for educational programs at the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. In 2024, he received the Myasthenia Gravis Foundation of America Medical Professional of the Year Award.

Habib maintains active involvement in professional organizations and serves on multiple advisory boards for pharmaceutical companies developing therapies for neuromuscular diseases. He is a member of the Medical & Scientific Advisory Council of the Myasthenia Gravis Foundation of America, where he chairs the Education sub-council, and serves on the Board of Directors of the Myasthenia Gravis Foundation of California. He is a member of the University of California, Irvine Institutional Review Board and the UC Irvine Health Sciences Clinical Mentoring Committee. Habib also serves as Chair of the Data Safety Monitoring Board for a clinical trial sponsored by Immunis, Inc., and as a member of the Data Safety Monitoring Board for the BrainGate2 study sponsored by NINDS and NIDCD.

Education

M.B., B.S., The Aga Khan University Medical College, Karachi, Pakistan, 2001

Distinctions

Myasthenia Gravis Foundation of America Medical Professional of the Year Award, 2024

Areas of Expertise

Neuromuscular Disorders
Myasthenia Gravis Therapeutics
Complement Inhibition Mechanisms
Electrodiagnostic Testing
Chimeric Antigen Receptor Therapy
FcRn Blockade Strategies
Clinical Trial Methodology

Recent Publications

Habib AA, Druzdz A, Grosskreutz J, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Vissing J, Gayfieva M, Pulido-Valdeolivas I, Tarancon T, Woltering F, Bril V, MycarinG and MG0007 Study Investigators, “Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: results from the phase 3 MycarinG study and an open-label extension” (opens in new tab), Journal of Neuromuscular Diseases, vol. 12, no. 2, pp. 231-242, 2025.
Habib AA, Claeys KG, Bril V, Hussain Y, Gwathmey K, Sahagian G, Cortes-Vicente E, Brauer E, Gelinas D, Sumbul A, Jimenez RH, Hristova D, Masschaele D, Mantegazza R, Meisel A, Attarian S, ADAPT NXT Study Group, “ADAPT NXT: fixed cycles or every-other-week IV efgartigimod in generalized myasthenia gravis” (opens in new tab), Annals of Clinical and Translational Neurology, vol. 12, no. 6, pp. 1162-1170, 2025.
Parthan A, Royston M, Thanataveerat A, East EL, Parzynski CS, Habib AA, “Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States” (opens in new tab), Muscle and Nerve, vol. 69, no. 2, pp. 157-165, 2024.
Gonzalez Caldito N, Habib AA, “Diagnosis of chronic inflammatory demyelinating polyneuropathy”, Prac Neuro, vol. 23, no. 3, pp. 19-25, 2024.
Regnault A, Habib AA, Creel K, Kaminski H, Morel T, “Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis” (opens in new tab), Frontiers in Neurology, vol. 15, pp. 1368525, 2024.
Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, Gajra A, Nowak RJ, Howard JF, “United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy” (opens in new tab), Journal of Neurology, vol. 271, no. 9, pp. 6114-6126, 2024.
Habib AA, Sacconi S, Antonini G, Cortes-Vicente E, Grosskreutz J, Mahuwala ZK, Mantegazza R, Pascuzzi RM, Utsugisawa K, Vissing J, Vu T, Wiendl H, Boehnlein M, Greve B, Woltering F, Bril V, “Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalized myasthenia gravis: a subgroup analysis of the randomized, double-blind, placebo-controlled, adaptive phase 3 MycarinG study” (opens in new tab), Therapeutic Advances in Neurological Disorders, vol. 17, pp. 17562864241273036, 2024.
Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M, Liao S, Beasley KN, Howard JF, “Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis” (opens in new tab), European Journal of Neurology, vol. 31, no. 12, pp. e16490, 2024.
Nowak RJ, Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, Gajra A, Howard JF, “US clinical practice experience with eculizumab in myasthenia gravis: acute clinical events and healthcare resource utilization” (opens in new tab), Drugs Real World Outcomes, vol. 11, no. 4, pp. 593-601, 2024.
Habib AA, “Refractory myasthenia gravis: the more we learn, the less we know”, RRNMF Journal, vol. 4, no. 3, pp. 90-97, 2023.
Habib AA, Waheed W, “Guillain-Barre Syndrome” (opens in new tab), Continuum Lifelong Learning in Neurology, vol. 29, no. 5, pp. 1327-1356, 2023.

Most Cited Publications

Habib AA, Mitsumoto H, “Emerging Drugs for Amyotrophic Lateral Sclerosis” (opens in new tab), Expert Opinion on Emerging Drugs, vol. 16, no. 3, pp. 537-58, 2011.
Habib AA, Gilden D, Schmid DS, Safdieh JE, “Varicella Zoster Virus meningitis with hypoglycorrhachia in the absence of rash in an immune competent woman” (opens in new tab), Journal of Neurovirology, vol. 15, no. 2, pp. 206-8, 2009.
Habib AA, Brannagan TH, “Therapeutic strategies for diabetic neuropathy” (opens in new tab), Current Neurology and Neuroscience Reports, vol. 10, no. 2, pp. 92-100, 2010.
Habib AA, Zhao C, Aban I, Franca MC Jr, Jose JG, Horste GM, Klimiec-Moskal E, Pulley MT, Tavolini D, Krumova P, Lennon-Chrimes S, Smith J, Thanei GA, Blondeau K, Vodopivec I, Wolfe GI, Murai H, “Safety and efficacy of satralizumab in patients with generalized myasthenia gravis (LUMINESCE): a randomized, double-blind, multicenter, placebo-controlled phase 3 trial” (opens in new tab), Lancet Neurology, vol. 24, no. 2, pp. 117-127, 2025.
Qureshi HU, Habib AA, Siddiqui AA, Mozaffar T, Sarwari AR, “Predictors of Mortality in Brain Abscess”, Journal of the Pakistan Medical Association, vol. 52, no. 3, pp. 111-6, 2002.
Mina-Osorio P, Tran MH, Habib AA, “Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease” (opens in new tab), Transfusion Medicine Reviews, vol. 38, no. 1, pp. 150767, 2024.
Habib AA, Sacks N, Cool C, Durgapal S, Dennen S, Everson K, Hughes T, Hernandez J, Phillips G, “Hospitalizations and mortality from myasthenia gravis. Trends from 2 US national datasets” (opens in new tab), Neurology, vol. 102, no. 2, pp. e207863, 2024.
Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski H, Habib AA, “Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG Symptoms PRO” (opens in new tab), Neurology and Therapy, vol. 12, no. 5, pp. 1573-1590, 2023.
Habib AA, Ahmadi Jazi G, Mozaffar T, “Update on immune-mediated therapies for myasthenia gravis.” (opens in new tab), Muscle and Nerve, vol. 62, no. 5, pp. 579-592, 2020.

Contact Information

Email: ali.habib@uci.edu

Phone: (714) 456-6832

Address: 200 S. Manchester Ave. Ste 206

This profile was created with the help of AI.

Last updated on 4/23/2026.